# Pulmonary Immunopathology Core (PIP)

> **NIH NIH P20** · LOUISIANA STATE UNIV A&M COL BATON ROUGE · 2024 · $253,676

## Abstract

SUMMARY 
The Center for Lung Biology and Disease (CLBD) at Louisiana State University (LSU) aims to elucidate the 
molecular and cellular pathogenesis of life-threatening respiratory diseases, including those resulting from 
infectious (bacterial, viral) and non-infectious stimuli (e.g., environmental, cigarette, e-cigarette aerosols). The 
Pulmonary Immunopathology Core (PIPC) offers expertise and technical support for investigators in the COBRE 
program. During Phase I, the PIPC provided equipment, facilities, and specialized training for COBRE Promising 
Junior Investigators (PJIs; i.e., Research Project Leads) in pulmonary immunopathological techniques. The core 
has already assisted six PJls, ten Pilot Project Investigators, and other NIH-funded investigators to successfully 
pursue their research objectives resulting in high impact peer-reviewed publications and successful NIH funding. 
The establishment of this core has facilitated productive collaboration among investigators and members of the 
biomedical research community in Louisiana. This core has also educated underrepresented minority (URM) 
undergraduate students, graduate students, postdoctoral fellows, summer scholars (DVM Students) in the 
application of and the current advances in pulmonary immunology through lectures, laboratory classes, and 
workshops. During Phase II, the PIPC will continue to meet two specific aims: Aim 1. To provide the COBRE 
and other biomedical investigators with resources on comprehensive immunopathological assessments for mice, 
including instrumentation, technical support and consultation. Aim 2. To educate faculty, staff, postdoctoral 
fellows, and graduate students regarding the application and the current advances in immunopathological 
assessments for mice. To ensure the success of the COBRE in Lung Biology and Disease COBRE PJIs, the 
continued operation of the PIPC is essential to meet the current and future needs of LSU and other institutions 
because this is the only PIPC in the state of Louisiana. In Phase II, the PIPC will provide required capabilities to 
measure the immunopathological outcomes infectious and non-infectious inflammation in mice, will promote 
immunological, pathological endpoints of project-specific parameters, and will streamline tasks to maximize 
efficiency, productivity, benefits, and economy.

## Key facts

- **NIH application ID:** 10851553
- **Project number:** 2P20GM130555-06
- **Recipient organization:** LOUISIANA STATE UNIV A&M COL BATON ROUGE
- **Principal Investigator:** Masami Yoshimura
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $253,676
- **Award type:** 2
- **Project period:** 2019-01-02 → 2029-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10851553

## Citation

> US National Institutes of Health, RePORTER application 10851553, Pulmonary Immunopathology Core (PIP) (2P20GM130555-06). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10851553. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*